Immatics to Make Significant Presentation at Melanoma Congress
Immatics N.V. (NASDAQ: IMTX), a prominent biopharmaceutical company specializing in T cell-redirecting cancer immunotherapies, has announced an exciting oral presentation at the upcoming International Congress of the Society for Melanoma Research. This presentation will focus on the latest clinical data regarding their innovative cell therapy candidate, ACTengine® IMA203, which specifically targets the preferentially expressed antigen in melanoma (PRAME).
Details of the Presentation
The oral presentation is scheduled for October 11, 2024, during Plenary Session 1, which will cover Developmental Immunotherapy and various cutting-edge approaches. It will take place from 8:00 to 8:20 AM Central Daylight Time. Dr. Martin Wermke from the University Hospital Dresden in Germany will lead the presentation, highlighting the significant progress made in treating PD1-refractory metastatic melanoma.
Insights into ACTengine IMA203
ACTengine® IMA203 is an autologous T cell product that features a genetically modified T cell receptor designed to recognize a specific HLA-A*02-presented peptide derived from PRAME. This peptide is notably found in many solid tumors and is expressed at high levels in tumor cells. Immatics has utilized its innovative XPRESIDENT® platform for mass spectrometry-based target discovery, which has significantly improved the identification of this essential target.
Currently, ACTengine® IMA203 is being evaluated in a Phase 1 clinical trial, where it is tested both as a standalone treatment and in a second-generation variant (IMA203CD8). This novel approach involves co-transducing IMA203-engineered T cells with a CD8?? co-receptor, allowing the therapy to harness the strengths of both CD4+ and CD8+ T cell populations for a more effective cancer fight. Importantly, Immatics has decided to deprioritize the combination of IMA203 with immune checkpoint inhibitors, concentrating on its efficacy as a standalone treatment.
Immatics' Vision and Commitment
Immatics is dedicated to developing targeted cancer immunotherapies through careful target discovery and the engineering of powerful T cell receptors. Their goal is to stimulate strong T cell responses against identified cancer targets, which is the driving force behind their promising pipeline of Adoptive Cell Therapies and TCR Bispecifics. Through strategic collaborations with leading pharmaceutical companies, Immatics aims to deliver transformative therapies to patients battling cancer.
Stay Informed with Immatics
Immatics intends to use its official website as a primary channel for sharing non-public material information. Those interested can also keep up with the company's developments by following them on various social media platforms, including X, Instagram, and LinkedIn.
Contact Information
For media inquiries: Trophic Communications, Phone: +49 171 3512733, Email: immatics@trophic.eu
For investor relations: Jordan Silverstein, Head of Strategy, Immatics N.V., Phone: +1 346 319-3325, Email: InvestorRelations@immatics.com
Frequently Asked Questions
What is the focus of the presentation at the Congress?
The presentation will discuss updated clinical data for ACTengine® IMA203, which targets PRAME in metastatic melanoma.
Who will be presenting the data?
The findings will be presented by Dr. Martin Wermke from the University Hospital Dresden.
When will the presentation take place?
The oral presentation is scheduled for October 11, 2024, from 8:00 to 8:20 AM CDT.
What is the significance of ACTengine® IMA203?
ACTengine IMA203 marks a significant advancement in personalized cancer treatments, focusing on PRAME, which is expressed in various tumors.
How can I stay updated on Immatics' developments?
You can follow Immatics on their social media platforms or visit their website for the latest news and updates.
